Business
BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC
April 8, 2026 Company Announcement No. 7 BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC COPENHAGEN, DENMARK and BOSTON, MA, USA, April 8, 2026 – BioPorto A/S (“BioPorto” or the “Company”) (CPH: BIOPOR) today announces the successful signing and simultaneous closing of an agreement to divest its antibody business to Janel Life Sciences LLC, a subsidiary of the Janel Corporation. The transaction encompasses BioPorto’s antibody business and represent
About this update from Bioporto A/s
[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v1ZhoICY2NNyMa6IbavSEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":300,"height":55}},"lazy":false},{"type":"text","content":"April 8, 2026","length":13,"tagName":"p"},{"type":"text","content":"Company Announcement No. 7","length":26,"tagName":"p"},{"type":"text","content":"BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC","length":95,"tagName":"p"},{"type":"text","content":"COPENHAGEN, DENMARK and BOSTON, MA, USA, April 8, 2026 – BioPorto A/S (“BioPorto” or the “Company”) (CPH: BIOPOR) today announces the successful signing and simultaneous closing of an agreement to divest its antibody business to Janel Life Sciences LLC, a subsidiary of the Janel Corporation.","length":292,"tagName":"p"},{"type":"text","content":"The transaction encompasses BioPorto’s antibody business and represents an important milestone in executing the Company’s strategy to strengthen its focus on driving market adoption of the Company’s NGAL biomarker and unlocking new opportunities for long‑term growth.","length":267,"tagName":"p"},{"type":"text","content":"The total consideration amounts to USD 10.5 million, with USD 9 million paid at closing. A further USD 1.5 million may be received over the coming three years as an earn‑out, provided specific commercial milestones are met.","length":223,"tagName":"p"},{"type":"text","content":"The agreement enhances BioPorto’s financial flexibility and provides funding that supports the Company’s continued progress towards sustainable positive cash flow. With the divestment of the antibody business, the Company is expected to cover current projected spending through first half of 2028. With the divestment the Company aspires to become cash flow positive during first half 2028 without need for further equity funding, assuming successful execution of the strategic milestones previously communicated.","length":513,"tagName":"p"},{"type":"text","content":"Carsten Buhl, CEO, commented: “We are very pleased...